A detailed history of Engineers Gate Manager LP transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Engineers Gate Manager LP holds 59,411 shares of SNDX stock, worth $947,605. This represents 0.02% of its overall portfolio holdings.

Number of Shares
59,411
Previous 75,840 21.66%
Holding current value
$947,605
Previous $1.56 Million 26.54%
% of portfolio
0.02%
Previous 0.04%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$17.93 - $24.81 $294,571 - $407,603
-16,429 Reduced 21.66%
59,411 $1.14 Million
Q2 2024

Aug 14, 2024

BUY
$18.82 - $23.79 $627,703 - $793,467
33,353 Added 78.5%
75,840 $1.56 Million
Q1 2024

May 15, 2024

BUY
$19.71 - $24.57 $517,328 - $644,888
26,247 Added 161.62%
42,487 $1.01 Million
Q4 2023

Feb 14, 2024

SELL
$11.39 - $21.67 $618,431 - $1.18 Million
-54,296 Reduced 76.98%
16,240 $350,000
Q3 2023

Nov 14, 2023

BUY
$14.52 - $21.77 $142,194 - $213,193
9,793 Added 16.12%
70,536 $1.02 Million
Q2 2023

Aug 14, 2023

BUY
$19.35 - $22.31 $180,303 - $207,884
9,318 Added 18.12%
60,743 $1.27 Million
Q1 2023

May 15, 2023

BUY
$20.66 - $28.98 $1.06 Million - $1.49 Million
51,425 New
51,425 $1.09 Million
Q2 2022

Aug 15, 2022

SELL
$13.64 - $19.48 $556,566 - $794,861
-40,804 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$14.84 - $22.15 $259,789 - $387,757
17,506 Added 75.14%
40,804 $709,000
Q4 2021

Feb 14, 2022

BUY
$15.23 - $22.47 $354,828 - $523,506
23,298 New
23,298 $510,000
Q3 2021

Nov 15, 2021

SELL
$13.87 - $19.8 $230,366 - $328,858
-16,609 Closed
0 $0
Q2 2021

Aug 16, 2021

SELL
$13.42 - $25.18 $90,705 - $170,191
-6,759 Reduced 28.92%
16,609 $285,000
Q1 2021

May 17, 2021

BUY
$19.28 - $24.59 $107,042 - $136,523
5,552 Added 31.16%
23,368 $523,000
Q4 2020

Feb 16, 2021

BUY
$15.1 - $26.44 $269,021 - $471,055
17,816 New
17,816 $396,000

Others Institutions Holding SNDX

About Syndax Pharmaceuticals Inc


  • Ticker SNDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,565,200
  • Market Cap $902M
  • Description
  • Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...
More about SNDX
Track This Portfolio

Track Engineers Gate Manager LP Portfolio

Follow Engineers Gate Manager LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Engineers Gate Manager LP, based on Form 13F filings with the SEC.

News

Stay updated on Engineers Gate Manager LP with notifications on news.